GlassScriptPhysician profile
Katherine E Brennan
NPI 1497241020
$1,201.33
in general payments reported to CMS, 2019-2025
15 companies · $814 in 2025
The $814 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $154 · 2023: $123 · 2024: $111 · 2025: $814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,048.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,047.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $204.95 | 2025 | Assure Wcd |
| Novartis Pharmaceuticals Corporation | $188.70 | 2024-2025 | |
| Abbott Laboratories | $170.43 | 2021-2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Medtronic, INC. | $160.93 | 2025 | Corevalve Evolut R |
| Biosense Webster, INC. | $130.35 | 2025 | Carto 3 |
| Astrazeneca Pharmaceuticals LP | $89.55 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $60.39 | 2025 | Lifevest |
| Regeneron Healthcare Solutions, INC. | $47.57 | 2025 | Evkeeza |
| Scpharmaceuticals INC. | $31.45 | 2025 | |
| Pfizer INC. | $29.78 | 2024 | |
| Amgen INC. | $19.16 | 2025 | Repatha |
| Merck Sharp & Dohme LLC | $18.22 | 2025 | Verquvo |
| Actelion Pharmaceuticals US, INC. | $16.80 | 2024 | Opsumit, Uptravi |
| Boston Scientific Corporation | $16.65 | 2025 | General - Vascular Intervention |
| Kiniksa Pharmaceuticals, LTD. | $16.40 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Brennan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.